Skip to main content

Table 2 Progress free survival time and overall survival time of patients before and after PSM

From: Efficacy of AS versus SOX regimen as first-line chemotherapy for gastric cancer patients with peritoneal metastasis: a real-world study

Variable N OS (months) PFS (months)
Median 95%CI Median 95%CI
Before PSM      
AS 62 13.27 11.35–15.19 10.07 8.40–12.09
SOX 81 11.17 9.61–12.72 6.70 5.51–7.89
AS (non-intestinal) 58 13.27 11.46–15.09 10.07 8.12–12.02
SOX (non-intestinal) 55 9.90 7.71–12.09 6.53 4.31–8.76
AS (diffuse) 42 14.23 11.70–16.77 10.07 7.81–12.33
SOX (diffuse) 35 8.83 6.67–11.00 4.60 3.54–5.66
After PSM      
AS 54 14.13 11.96–16.31 10.30 7.06–13.54
SOX 54 11.17 9.09–13.24 6.70 6.08–7.33
AS (non-intestinal) 50 14.23 12.14–16.33 10.30 7.53–13.07
SOX (non-intestinal) 39 9.90 7.30–12.50 6.87 5.26–8.48
AS (diffuse) 34 15.93 13.58–18.28 10.30 7.27–13.33
SOX (diffuse) 24 8.83 6.51–11.15 4.60 2.25–6.95
  1. OS, overall survival time; PFS, progress free survival time; CI, confidence intervals; non-intestinal, including diffuse lauren type and mixed lauren type; PSM, propensity score matching; N, number